Severe Atopic Dermatitis
Amlitelimab maintains patient response in atopic dermatitis following treatment cessation
Adults treated with amlitelimab showed sustained improvement in their moderate to severe atopic dermatitis over the span of 28 weeks, Sanofi announced in a press release.
FDA clears investigational new drug application for ICP-332
The FDA has cleared InnoCare Pharma’s investigational new drug application for ICP-332, according to a press release.
FDA approves Adbry autoinjector for atopic dermatitis
The FDA has approved a single-dose autoinjector for Adbry, LEO Pharma announced in a press release.
Getting Under the Skin: Updates in the Treatment of Pediatric Atopic Dermatitis
This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.
VIDEO: Topical treatments may be effective against moderate to severe atopic dermatitis
In this video, Raj Chovatiya, MD, PhD, discussed research into the OX40 inhibitor amlitelimab, as well as two topical medications, from the Maui Derm 2024 meeting, examining data into their use in treating atopic dermatitis.
Atopic dermatitis may be linked to inflammatory bowel disease
An association between moderate to severe atopic dermatitis and inflammatory bowel disease suggests a multidisciplinary approach to AD may be necessary, according to a study.
Greater atopic dermatitis severity linked to worse quality of life in pediatric patients
Pediatric patients with severe atopic dermatitis experienced higher rates of itch, pain, sleep disturbances and missed school days compared with those with mild disease, according to a study.
Rademikibart maintains efficacy in atopic dermatitis through 1 year
Long-term trial results showed efficacy of rademikibart in Chinese patients with moderate to severe atopic dermatitis, Connect Biopharma announced in a press release.
European Commission approves Ebglyss for adults, adolescents with atopic dermatitis
The European Commission has approved Ebglyss in the European Union for the treatment of moderate to severe atopic dermatitis in adults and adolescents aged 12 years and older, Almirall announced in a press release.
Lebrikizumab maintenance dosing achieves dermatitis clearance up to 2 years
Maintenance dosing of lebrikizumab sustained skin clearance, relieved itch and reduced disease severity for up to 2 years in patients with moderate to severe atopic dermatitis, Eli Lilly and Company announced in a press release.